
Egetis Therapeutics Q1 2024 - EU launch closing in

Redeye updates its view of Egetis following the Q1 report and recent events in the company. The company has an ongoing regulatory process in EU, which we expect will be finalized late 2024e/early 2025e, and presented continued recruitment in the registrational US study.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Egetis Therapeutics Q1 2024 - EU launch closing in](#)